<DOC>
	<DOCNO>NCT00678119</DOCNO>
	<brief_summary>Study investigate anticancer cellular immunotherapeutic , AGS-003 , use combination sunitinib subject previously untreated advanced stage RCC .</brief_summary>
	<brief_title>Study Testing Biologic Activity Safety Immunotherapeutic Patients With Newly Diagnosed Advanced Stage Kidney Cancer Combination With Marketed Renal Cell Carcinoma Treatment</brief_title>
	<detailed_description>The purpose study investigate anticancer immunotherapeutic , AGS-003 , use combination sunitinib ( treatment regimen ) single-stage , Phase II design subject previously untreated advanced stage RCC nephrectomy/excisional biopsy/metastasectomy . AGS-003 formulate use mature DCs co-electroporated CD40L IVT RNA autologous total tumor RNA</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Male female subject â‰¥18 year age newly diagnose advanced stage RCC eligible inclusion study follow criterion apply : 1 . Newly diagnose advanced stage RCC . 2 . Eligible unilateral nephrectomy partial nephrectomy ; OR , Has lesion accessible excisional biopsy/metastasectomy . 3 . Measurable disease . 4 . Candidate sunitinib treatment label . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . Memorial Sloan Kettering Cancer Center ( MSKCC ) risk group 0 1 . 7 . No brain metastasis detect MRI . 8 . Normal renal function contralateral kidney . 9 . Able abstain take prohibited prescription prohibit nonprescription drug . 10 . Use appropriate birth control method duration study woman childbearing potential men female partner childbearing potential . 11 . Clinically acceptable Screening result accord follow specific limit : Adequate hematologic function . Adequate renal hepatic function . Adequate coagulation function . 12 . Normal serum calcium . 13 . Ability communicate effectively study personnel ; consider reliable , willing , cooperative term compliance Protocol requirement . 14 . Voluntary inform consent give participate study . Subjects NOT eligible inclusion study follow criterion apply : 1 . Nephrectomy RCC therapy require . 2 . Any serious medical condition illness consider investigator constitute unwarranted high risk investigational treatment . 3 . Uncontrolled hypertension . 4 . Type I diabetes mellitus ( insulin therapy Type II diabetes IS permit ) . 5 . Prior systemic therapy advance stage RCC . 6 . Active autoimmune disease . 7 . Prior history malignancy RCC within precede 5 year , except adequately treated cervical cancer nonmelanoma skin cancer . 8 . Use prohibit prescription prohibit nonprescription drug 2 month prior entry study . 9 . Active , acute , chronic clinically significant infection . 10 . Use another investigational drug participation investigational drug study within 28 day prior start study enrollment . 11 . Planned elective anticancer surgical treatment nephrectomy/excisional biopsy/metastasectomy . 12 . History hypercalcemia , symptomatic hypercalcemia , hypercalcemia require management . 13 . Known hypersensitivity dimethyl sulfoxide ( DMSO ) . 14 . Body weight less 30 kg . 15 . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Kidney cancer</keyword>
	<keyword>Renal cancer</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
</DOC>